# GLP-1 drugmakers sued over sudden vision loss claims

> Pharmaceutical giants face lawsuits claiming GLP-1 weight-loss drugs caused irreversible vision damage.
- Title: GLP-1 drugmakers sued over sudden vision loss claims
- Summary: Pharmaceutical giants face lawsuits claiming GLP-1 weight-loss drugs caused irreversible vision damage. Patients report sudden vision loss linked to GLP-1…
- Keywords: glp1, vision loss, naion, ozempic, wegovy, novonordisk, elililly, sudden vision loss, pharmaceutical lawsuits, nonarteritic anterior ischemic optic neu, news, local
- Source: PhillyVoice — https://phillyvoice.com/glp1-weight-loss-drugs-vision-loss-ozempic-wegovy
- Published: 2026-09-23T19:48:33.83+00:00
- Read time: 1 min
- Topics: glp1, vision loss, naion, ozempic, wegovy, novonordisk, elililly, sudden vision loss, pharmaceutical lawsuits, nonarteritic anterior ischemic optic neu, news, local
## Sudden vision loss claims
Patients report sudden, irreversible vision damage after using GLP-1 weight-loss drugs.

> The lawsuits claim Novo Nordisk and Eli Lilly should have warned consumers about vision loss as a potential side effect.
## Lawsuits targeting drugmakers
Over 100 lawsuits filed in New Jersey since 2025 allege GLP-1 drugs caused non-arteritic anterior ischemic optic neuropathy.
## Drug companies deny link
Novo Nordisk and Eli Lilly state there is no causal relationship between GLP-1s and vision loss.

> A causal relationship between GLP-1RAs, including semaglutide, and NAION cannot be confirmed based on the totality of data
## NAION explained
Non-arteritic anterior ischemic optic neuropathy causes sudden, painless vision loss in people 50 and older.
## Global warnings differ
Some countries require GLP-1 drugs to list vision loss as a rare side effect, while the US does not.
## Clinical trial findings
Recent studies show no increased risk of NAION in patients using Wegovy or Ozempic in clinical trials.
## Regulatory actions
European Medicines Agency recommended adding NAION warnings to Novo Nordisk's weight-loss drugs in 2025.
## Drug safety focus
Novo Nordisk emphasizes patient safety as a top priority while fighting the lawsuits.
## Ophthalmic concerns
NAION affects 2 to 10 people per 100,000 in the US and causes blurred vision or partial blindness.
## Legal action details
Law firms in New Jersey have filed lawsuits on behalf of patients claiming GLP-1 drugs caused vision loss.
## Key takeaway

Patients report sudden vision loss linked to GLP-1 drugs, but companies say no causal relationship exists.